published meta-analysis   sensitivity analysis   studies

Vitamin D in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsEntrenas (Pilot Calcifediol), 2020 0.12 [0.01; 2.79] Murai, 2020 1.53 [0.53; 4.43] 0.67[0.07; 6.87]Entrenas (Pilot Calcifediol), 2020, Murai, 2020255%313moderatenot evaluable hospital dischargedetailed resultsMurai, 2020 0.99 [0.71; 1.38] 0.99[0.71; 1.38]Murai, 202010%240NAnot evaluable mechanical ventilationdetailed resultsMurai, 2020 0.49 [0.21; 1.14] 0.49[0.21; 1.14]Murai, 202010%237NAnot evaluable ICU admissiondetailed resultsEntrenas (Pilot Calcifediol), 2020 0.03 [0.00; 0.27] Murai, 2020 0.71 [0.37; 1.37] 0.17[0.01; 3.79]Entrenas (Pilot Calcifediol), 2020, Murai, 2020286%313moderatenot evaluable serious adverse eventsdetailed resultsMurai, 2020 0.99 [0.02; 50.39] 0.99[0.02; 50.39]Murai, 202010%237NAnot evaluable adverse eventsdetailed resultsMurai, 2020 1.99 [0.07; 59.94] 1.99[0.07; 59.94]Murai, 202010%237NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-29 01:02 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 734,1439 - roots T: 290